On September 15, RGCC International announced the successful conclusion of the RGCC International Gathering 2025, held from September 12-14, 2025, in Zurich, Switzerland.
Bringing together more than 130 attendees from across the globe, the RGCC International Gathering reaffirmed its position as Europe’s largest and most dynamic meeting of RGCC scientists, clinicians and collaborators. Over the course of three impactful days, participants explored cutting-edge advancements in cancer diagnostics and autologous treatments, shared clinical insights and strengthened global collaboration in the fight against cancer.
The event opened with a keynote by Ioannis Papasotiriou, MD, PhD, founder and director of RGCC International, who presented RGCC’s most significant research achievements and innovations from the past two years. The program featured expert-led sessions from RGCC scientists and collaborators, covering a range of pioneering topics such as:
• Extracellular Vesicles Cancer Theranostics
• Biomimetic 3D in Vitro Cellular Models to Explore New Cancer Targets
• The Importance of Quality in Food Supplements
• Modern Drug Discovery for New and Selective Cancer Therapy
The Gathering also highlighted practitioner experiences with RGCC technologies, including:
• Functional Application of Liquid Biopsy in Personalizing Cancer Treatment presented by Conrado Lola, MD (Philippines)
• Clinician’s Practical Guide to Utilizing RGCC Cancer Testing, presented by Clayton Bell, MD, IFMCP, ABOIM, ABFM, EMEI, LLMD (USA)
These were among several insightful practitioner-led presentations, offering real-world perspectives on the application of RGCC technologies in clinical practice. Beyond presentations, the event fostered collaboration through interactive panels and networking opportunities.
The Gathering concluded with an open Q&A session led by Papasotiriou, providing attendees the opportunity to exchange feedback and engage directly with RGCC leadership.
“The RGCC Gathering is more than a conference. It is a global community working together to advance the future of personalized cancer care,” said Papasotiriou. “The insights, research and collaborations forged here will play a vital role in shaping the next chapter of precision oncology.”
